Targeting mitochondria with mitocans to treat cancer: mechanistic aspects. Mitochondria are the power-house of the cell and also the reservoir of proteins causing the demise of cancer cells, therefore suppressing tumour progression. This project proposes a novel way to modify certain compounds, increasing their level in mitochondria in order to maximise their anti-cancer effect.
Mitochondrially targeted anti-cancer drugs modulate the mitochondrial genome. Successful cancer management requires novel therapeutical approaches. This project will test the effect of a new class of compounds that target mitochondria, the powerhouse of the cells, where they suppress expression of mitochondrial genes. By this mechanism, cancers that are resistant to apoptosis induction can be inhibited.
Development and validation of virtual epithelial cancer models using an integrated modelling and experimental three-dimensional approach. The mathematical and experimental modelling of the human prostate and ovary applying quantitative bioengineering concepts will lead to virtual cancer models. This project aims to validate these multi-scale models to delineate biological and pathological avenues in healthy and disease tissue and improve prevention and treatment of prostate and ovarian cancer.